Vnitr Lek 2025, 71(2):E13-E18 | DOI: 10.36290/vnl.2025.024
The rate of progression of diabetic kidney disease in patients with type 1 diabetes mellitus
- 1 Interní klinika 3. LF UK a FNKV, Praha
- 2 Státní zdravotní ústav, Praha
- 3 PřF UK, Praha
- 4 Fresenius Medical Care - DS, Praha
The risk of developing diabetic nephropathy is directly proportional to the duration of type 1 diabetes, with metabolic control of the disease playing a crucial role. The peak incidence of diabetic nephropathy occurs between 10 and 20 years after the diagnosis of the underlying disease. The annual incidence of albuminuria development in patients with type 1 diabetes mellitus is 2-3%. The annual incidence of a decline in estimated glomerular filtration rate below 60 ml/min/1.73 m2 is 2-4 %, regardless of the type of diabetes. According to older studies from the late 1980s, an individual with type 1 diabetes mellitus (DMT1) has a 40% chance of developing proteinuria over 40 years of diabetes duration. More recent cross-sectional studies from several national registries indicate that 8 % of type 1 diabetics with a diabetes duration of less than 20 years develop microalbuminuria, and nearly 25 % do so after more than 40 years of diabetes. Despite the use of modern therapeutic approaches in diabetes treatment, a significant proportion of individuals with DMT1 develop renal complications in the form of albuminuria or impaired glomerular filtration within less than 20 years after diagnosis. Although the preservation of kidney function after the onset of proteinuria has also improved, it remains much worse compared to individuals with DMT1 without albuminuria. There is a lack of studies in the available literature that adequately describe the rate of development of diabetic kidney disease from the time of diabetes diagnosis.
Keywords: diabetes mellitus, diabetic kidney disease, albuminuria, glycated hemoglobin.
Accepted: March 18, 2025; Published: March 27, 2025 Show citation
ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. Available from: doi:10.1016/j.diabres.2021.109119.
Go to original source...
Go to PubMed...
- Gregory GA, Robinson TIG, Linklater SE, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 2022;10(10):741-760. Available from: doi:10.1016/S2213-8587(22)00218-2.
Go to original source...
Go to PubMed...
- Koye DN, Magliano DJ, Nelson RG, Pavkov ME. The global epidemiology of diabetes and kidney disease. Adv Chronic Kidney Dis. 2018;25(2):121-132. Available from: doi:10.1053/j.ackd.2017. 10. 011.
Go to original source...
- Chen L, Islam RM, Wang J, et al. A systematic review of trends in all-cause mortality among people with diabetes. Diabetologia. 2020;63(9):1718-1735. Available from: doi:10.1007/s00125-020-05199-0.
Go to original source...
Go to PubMed...
- American Diabetes Association. 11. Microvascular complications and foot care: Standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S151-S167. Available from: doi:10.2337/dc21-S011.
Go to original source...
Go to PubMed...
- Brück K, Stel VS, Gambaro G, et al. CKD prevalence varies across the European general population. J Am Soc Nephrol. 2016;27(7):2135-2147. Available from: doi:10.1681/ASN.2015050542.
Go to original source...
Go to PubMed...
- Tomic D, Shaw JE, Magliano DJ. The burden and risks of emerging complications of diabetes mellitus. Nat Rev Endocrinol. 2022;18(8):525-539. Available from: doi:10.1038/s41574-022-00690-7.
Go to original source...
Go to PubMed...
- Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825-830. Available from: doi:10.7326/0003-4819-158-11-201306040-00007.
Go to original source...
Go to PubMed...
- Česká společnost pro klinickou biochemii. Doporučené postupy při diabetickém onemocnění ledvin. Klin Biochem Metab. 2021;29(2):90-105. Available from: https://www.cskb.cz/wp-content/uploads/2021/08/KBM-2021-2-dop-DM-nefrol.pdf.
- National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(Suppl 2):S12-S154. Available from: https://doi.org/10.1053/j.ajkd.2006. 12. 005.
Go to original source...
- Thomas MC, Macisaac RJ, Jerums G, et al. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (NEFRON 11). Diabetes Care. 2009;32(8):1497-1502. Available from: doi:10.2337/dc08-2186.
Go to original source...
Go to PubMed...
- Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR; UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes. 2006;55(6):1832-1839. Available from: doi:10.2337/db05-1620.
Go to original source...
Go to PubMed...
- Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1:15018. Available from: doi:10.1038/nrdp.2015. 18.
Go to original source...
- Cheng HT, Xu X, Lim P, Hung KY. Worldwide epidemiology of diabetes-related end-stage renal disease, 2000-2015. Diabetes Care. 2020;44(2):255-262. Available from: doi:10.2337/dc20-1913.
Go to original source...
Go to PubMed...
- Česká nefrologická společnost. Ročenka ČNS za rok 2023. Available from: http://www.nefro.cz/media/1099/rocenka2023.pdf.
- Harjutsalo V, Groop PH. Epidemiology and risk factors for diabetic kidney disease. Adv Chronic Kidney Dis. 2014;21(3):260-266. Available from: doi:10.1053/j.ackd.2014. 03. 009.
Go to original source...
- Spanakis EK, Golden SH. Race/ethnic difference in diabetes and diabetic complications. Curr Diab Rep. 2013;13(6):814-823. Available from: doi:10.1007/s11892-013-0421-9.
Go to original source...
Go to PubMed...
- Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomized trial. Lancet. 2010;376(9739):419-430. Available from: doi:10.1016/S0140-6736(10)60576-4.
Go to original source...
Go to PubMed...
- Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139. Available from: doi:10.1056/NEJMoa0808431.
Go to original source...
Go to PubMed...
- Neugarten J, Golestaneh L. Gender and the prevalence and progression of renal disease. Adv Chronic Kidney Dis. 2013;20(3):390-395. Available from: doi:10.1053/j.ackd.2013. 03. 003.
Go to original source...
- Maric-Bilkan C. Sex differences in diabetic kidney disease. Mayo Clin Proc. 2020;95(2):307-318. Available from: doi:10.1016/j.mayocp.2019. 09. 024.
Go to original source...
- Freedman BI, Sedor JR. Genetic predisposition to diabetic nephropathy. Clin J Am Soc Nephrol. 2008;3(3):S20-S30. Available from: doi:10.2215/CJN.02660707.
Go to original source...
Go to PubMed...
- Parsa A, Kao WH, Xie D, et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med. 2013;369(23):2183-2196. Available from: doi:10.1056/NEJMoa1310345.
Go to original source...
Go to PubMed...
- Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia. 1983;25(6):496-501.
Go to original source...
Go to PubMed...
- Borch-Johnsen K, Kragh Andersen P, Deckert T. The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1985;28:590-596.
Go to original source...
Go to PubMed...
- Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986. Available from: doi:10.1056/NEJM199309303291401.
Go to original source...
Go to PubMed...
- DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol. 2014;2(10):793-800. Available from: doi:10.1016/S2213-8587(14)70155-X.
Go to original source...
Go to PubMed...
- Lind M, Pivodic A, Svensson AM, Ólafsdóttir AF, Wedel H, Ludvigsson J. HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population-based cohort study. BMJ (Clin Res Ed). 2019;366:l4894. Available from: https://doi.org/10.1136/bmj.l4894.
Go to original source...
Go to PubMed...
- Arnqvist HJ, Westerlund MC, Fredrikson M, et al. Impact of HbA1c Followed 32 Years From Diagnosis of Type 1 Diabetes on Development of Severe Retinopathy and Nephropathy: The VISS Study. Diabetes Care 2022; 45(11):2675-2682. Available from: doi:10.2337/dc22-0239.
Go to original source...
Go to PubMed...
- Dena M, Svensson AM, Olofsson KE, et al. Renal Complications and Duration of Diabetes: An International Comparison in Persons with Type 1 Diabetes. Diabetes Ther 2021; 12(12):3093-3105. Available from: doi:10.1007/s13300-021-01169-w.
Go to original source...
Go to PubMed...
- Brož J, Janíčková Žďárská D, Urbanová J, et al. Current Level of Glycemic Control and Clinical Inertia in Subjects Using Insulin for the Treatment of Type 1 and Type 2 Diabetes in the Czech Republic and the Slovak Republic: Results of a Multinational, Multicenter, Observational Survey (DIAINFORM). Diabetes Ther. 2018;9(5):1897-1906. Available from: doi:10.1007/s13300-018-0485-2.
Go to original source...
Go to PubMed...
- Holubová A, Vlasáková M, Mužík J, Brož J. Customizing the Types of Technologies Used by Patients With Type 1 Diabetes Mellitus for Diabetes Treatment: Case Series on Patient Experience. JMIR Mhealth Uhealth 2019; 7(7). Available from: doi:10.2196/11527.
Go to original source...
Go to PubMed...
- Rossing P, Hougaard P, Parving HH. Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study. Kidney Int. 2005;68(4):1446-1450. Available from: https://doi.org/10.1111/j.1523-1755.2005.00556.x.
Go to original source...
Go to PubMed...
- Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 2006; 55(5):1463-1469. Available from: doi:10.2337/db05-1423.
Go to original source...
Go to PubMed...
- Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med. 1994;330(1):15-18. Available from: https://doi.org/10.1056/NEJM199401063300103.
Go to original source...
Go to PubMed...
- Marshall SM. Diabetic nephropathy in type 1 diabetes: has the outlook improved since the 1980 s? Diabetologia. 2012;55:2301-2306. Available from: https://doi.org/10.1007/s00125-012-2606-1.
Go to original source...
Go to PubMed...
- Van Dijk PC, Jager KJ, Stengel B, et al. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). Kidney Int. 2005;67(4):1489-1499. Available from: https://doi.org/10.1111/j.1523-1755.2005.00227.x.
Go to original source...
Go to PubMed...